Earnings Summary

Fulcrum Therapeutics Inc’s revenue fell -53.24% since last year same period to $0.88Mn in the Q2 2023. On a quarterly growth basis, Fulcrum Therapeutics Inc has generated 198.31% jump in its revenue since last 3-months.

Fulcrum Therapeutics Inc’s net profit jumped 30.19% since last year same period to $-23.78Mn in the Q2 2023. On a quarterly growth basis, Fulcrum Therapeutics Inc has generated -10.01% fall in its net profits since last 3-months.

Fulcrum Therapeutics Inc’s net profit margin fell -49.29% since last year same period to -2702.61% in the Q2 2023. On a quarterly growth basis, Fulcrum Therapeutics Inc has generated 63.12% jump in its net profit margins since last 3-months.

Fulcrum Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.49 - a 19.67% jump from last quarter’s estimates.

Fulcrum Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.49.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Fulcrum Therapeutics Inc’s return on assets (ROA) stands at -0.27.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Fulcrum Therapeutics Inc’s return on equity (ROE) stands at -0.45.